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Abstract: The mammalian lignan, enterolactone, has been shown to reduce the proliferation 
of the earlier stages of prostate cancer at physiological concentrations in vitro. However, 
efficacy in the later stages of the disease occurs at concentrations difficult to achieve through 
dietary modification. We have therefore investigated what concentration(s) of enterolactone 
can restrict proliferation in multiple stages of prostate cancer using an in vitro model system 
of prostate disease. We determined that enterolactone at 20 μM significantly restricted the 
proliferation of mid and late stage models of prostate disease. These effects were strongly 
associated with changes in the expression of the DNA licencing genes (GMNN, CDT1, 
MCM2 and 7), in reduced expression of the miR-106b cluster (miR-106b, miR-93, and  
miR-25), and in increased expression of the PTEN tumour suppressor gene. We have shown 
anti-proliferative effects of enterolactone in earlier stages of prostate disease than previously 
reported and that these effects are mediated, in part, by microRNA-mediated regulation. 
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1. Introduction 
Prostate cancer is the second most common cancer in men worldwide with seventy percent of annual 
diagnoses occurring in Westernised societies [1]. The incidence of the disease is considerably higher in 
the EU, North America and New Zealand than in China (14, 22 and 25-fold, respectively) [2–5] Whilst 
risk factors for prostate cancer such as age, ethnic origin and heredity are important, geographical and 
economic differences in diet and lifestyle appear to influence prostate disease risk to a greater extent [6–8]. 
A clear link between diet and prostate cancer is yet to be shown, due in part to a lack of understanding 
of the effects, or absence of effect of dietary components on the mechanisms of prostate tumourigenesis. 
Enterolactone (ENL) is a weakly-oestrogenic (100 to 1000-fold less compared to natural oestradiol) 
mammalian metabolite that is produced by the metabolism of plant lignans by intestinal bacteria, but 
may also be present in low amounts in dairy foods and meat as a consequence of ruminant intestinal 
metabolism (reviewed [9–11]), [12–16]. ENL has been reported to have anti-cancer, anti-oxidant,  
anti-inflammatory and anti-angiogenic properties [10,11,17–21], but ecological studies examining ENL 
exposure and disease risk, especially with regard to prostate cancer, have been inconclusive [9–11]. This 
is due, in part, to a lack of understanding of how the inter-individual response to ENL may be affected 
by diet and lifestyle, genetic and/or epigenetic factors and intestinal microbiota composition. 
Serum or urinary ENL levels, a biomarker of exposure, vary considerably by population and dietary 
preference, and typically ranges from 0.1 to 10 μM [9–11]. There is, however, some evidence that ENL 
can accumulate to higher levels (up to 25-fold higher) in prostate tissue and fluid, suggesting a biological 
function for ENL in the prostate [22]. Although there are human, animal and in vitro studies showing 
that purified ENL, or foods rich in ENL, can inhibit the development and progression of prostate cancer 
for example by reducing proliferation [18–21] or affecting steroid metabolism and activity [23], it is not 
yet clear if these effects occur at concentrations achievable through dietary intake alone [9–11]. There 
is a distinct lack of data available on the concentration of ENL in prostate tissue pre and post-intervention 
with ENL precursors, which restricts our understanding of how bio-available ENL is in the prostate. We 
have recently shown that physiologically-relevant concentrations of ENL can reduce the proliferation of 
early-stage prostate disease in vitro and that these effects are associated with alterations in the expression 
of DNA replication licencing genes [19]. 
The correct initiation of DNA replication requires the licencing of origin of replications by the 
minichromosome maintenance complex (MCM) [24]. The loading of this MCM complex is facilitated, 
in part, by chromatin licensing and DNA replication factor 1 (CDT1), which is itself negatively regulated 
by geminin (GMMN). Abnormal expression of GMNN, CDT1, and MCM2 and 7 have been linked with 
the malignant progression of prostate cancer [25–31]. Another key signalling pathway disrupted in 
prostate cancer is the phosphoinositide-3-kinase (PI3K)-AKT signalling pathway. The phosphatase and 
tensin homolog (PTEN) tumour suppressor gene negatively regulates the PI3K/AKT pathway and PTEN 
is one of the most common tumour suppressor genes whose appropriate function is compromised in 
prostate cancer (~70% of cases) [32–34], which leads to abnormal proliferation and cell death. Initiation 
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of DNA replication and PTEN tumour suppression are transcriptionally-linked as one of the MCMs 
(MCM7) has a microRNA cluster (miR-106b, -93, and 25) in one of its introns that suppresses PTEN 
translation and dysregulation of the cluster is also linked to cancer [35]. 
Cancer is not composed of abnormal cells at the same stage of disease; rather it is a series of abnormal 
cells at differing stages of disease that collectively compromise the appropriate function of the tissue. 
Previous research has shown anti-proliferative effects of ENL in one or in limited stages of disease, 
rather than efficacy in a range of disease states [18–21]. Therefore, we hypothesised that ENL could 
restrict the proliferation of more than just the later stages of prostate disease. To investigate our 
hypothesis we used an in vitro model system of six prostate cell lines representing the early (RWPE-1 
and WPE1-NA22), mid (WPE1-NB14 and WPE1-NB11) and later (WPE1-NB26 and LNCaP) stages of 
prostate tumourigenesis [36,37]. The LNCaP cell line is a model of the switch between androgen 
sensitivity and insensitivity during prostate disease that occurs in the later stages of carcinogenesis [37]. 
This in vitro model system was used to assess how the metabolic activity, growth rate, cell cycle 
progression changes with ENL exposure over 24 and 48 h. Based on these data we explored potential 
mechanisms for the anti-proliferative activity by measuring the expression of the GMMN, CDT1, 
MCM2 and MCM7, miR-106b cluster, and PTEN genes. 
2. Experimental Section 
2.1. Cell Culture and Enterolactone Preparation 
Authenticated RWPE-1 (P52), WPE1-NA22 (P20), WPE1-NB14 (P16), WPE1-NB11 (P24),  
WPE1-NB26 (P15), and LNCaP (P22) cell lines were purchased from the American Type Culture 
Collection (Manassas, VA, USA) to test the effects of ENL. All cell culture reagents were obtained from 
Life Technologies (Auckland, New Zealand) unless otherwise stated. The cell lines were cultured and 
maintained as described previously [19], with all experiments were completed within ten sub-cultures 
from the original ATCC stock. 
A stock solution of ENL (45199, Sigma-Aldrich, Auckland, New Zealand) at 16.76 mM (100% 
DMSO) was prepared and used to prepare test concentrations of ENL in cell-line specific medium. 
Etoposide (Sigma-Aldrich, Auckland New Zealand) was used as a positive control for proliferation as it 
blocks DNA synthesis resulting in apoptosis. The negative control for all experiments was cell-line 
specific medium adjusted to contain 0.36% v/v of DMSO. 
2.2. Cell Viability—Mitochondrial Activity Assay 
The effect of 10 to 100 μM ENL on the metabolic activity of the six cell lines over 48 h was measured 
using the water soluble tetrazolium cytotoxicity assay (WST-1, Clontech, Mountain View, CA, USA) 
as described previously [19]. The negative control and each concentration of ENL were tested on  
twenty-four biological replicates for both time points. The absorbance of the formazan dye produced was 
measured at 450 and 650 nm using a SpectraMax 250 spectrophotometer (Molecular Devices, Sunnyvale, 
CA, USA). For all measurements (including the blank), the background absorbance (650 nm) was 
subtracted from the detection wavelength (450 nm) and these corrected values were used  
for analysis. 
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2.3. Cell Viability—Growth Kinetics Assay 
The effect of 10 to 60 μM ENL on the viability of each cell line over 48 h was measured using trypan 
blue staining and the number of non-blue (viable) cells counted as described previously [19]. For each 
of three separate assays for each time point, each concentration was tested on two technical replicates 
with an initial seeding density of 5 × 105 cells. From these data the effect of ENL on the doubling time 
of the cell lines was calculated. 
2.4. Cell Viability—Cell Cycle Profile Assay 
The effect of 20 μM ENL on the cell cycle profile of six cell lines over 48 h was measured with the 
Dead Cell Apoptosis Kit with Annexin V Alexa Fluor® 488 & Propidium Iodide from Life Technologies 
(Auckland, New Zealand). This kit is a flow cytometry kit used to measure early apoptosis by detecting 
phosphatidyl serine expression and membrane permeability [18,38]. 
Each assay was completed according to the manufacturer’s instructions. For each of three separate 
assays for each time point, each concentration was tested on three technical replicates with an initial 
seeding density of 5 × 105 cells. The fluorescence intensities of Alexa Fluor 488 and Propidium Iodide 
in each sample, at 585 nm, were measured using a FACSCalibur flow cytometer with CELLQuest Pro 
Software (BD Biosciences, Auckland, New Zealand), and analysed using FlowJo V7.6.3 (TreeStar, 
Ashland, OR, USA). 
2.5. Quantification of Gene Expression—mRNA and miRNA Genes 
The expression of GMNN, CDT1, MCMs 2 and 7, PTEN, hsa-miR-106b, hsa-miR-93, and  
hsa-miR-25 by the six cell lines treated with 20 μM ENL over 48 h was quantified using probe-based 
real-time PCR. All reagents were obtained from Life Technologies (Auckland, New Zealand) unless 
otherwise stated. For each gene and time point, two biological replicates (with triplicate qPCR 
measurements) of 5 × 105 cells were used. 
The NucleoSpin® miRNA kit (Macherey-Nagel, Düren, Germany) was used to extract large and small 
RNA in separate fractions from each of the samples according to the manufacturer’s instructions. RNA 
quantity and integrity was determined based on A260:280 and A260:230 nm ratios using a NanoDrop 
1000 spectrophotometer (Thermo Fisher Scientific, Melbourne, Australia) and a Agilent 2100 
bioanalyser (Agilent, Santa Clara, CA, USA). Only RNA with both absorbance ratios of 1.8 to 2.1 and 
with a RIN value of 9 or greater were considered to be of sufficient quality and integrity. 
For the large RNA fractions, 500 ng was reverse transcribed into cDNA using a high capacity  
RNA-to-cDNA kit according to the manufacturer’s instructions. The expression levels of the mRNA 
transcripts of the GMNN, CDT1, MCMs 2 and 7, and PTEN genes were quantified using pre-validated 
PrimeTime Nuclease assays (Hs.PT.51.14706721.g, Hs.PT.53.27448129.gs, Hs.PT.53.25820936, 
Hs.PT.53.23112694.g, and Hs.PT.51.14706721.g) (Integrated DNA Technologies, Singapore, 
Singapore). The HPRT1 (Hs.PT.39a.22214821) reference gene was used to normalise for RNA content. 
For the small RNA fractions, 10 ng was reverse transcribed into cDNA with gene specific primers 
using the TaqMan microRNA RT kit according to the manufacturer’s instructions. The expression levels 
of the mature hsa-miR-106, hsa-miR-93, and hsa-miR-25 genes were quantified using pre-validated 
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TaqMan assays (000442, 002139, and 002442). The RNU6B reference gene (001093) was used to 
normalise for RNA content. 
All real-time PCR assays were prepared as triplicate 10 μL reactions comprising a 9.0 μL aliquot of 
master mix (5.0 μL of 2x Kapa Fast Probe mix (Kapa Biosystems, Wilmington, DE, USA), 0.5 μL of 
20x mRNA or miRNA gene assay, 3.5 μL of nuclease-free water, and 1 μL of cDNA (10-fold dilution 
in nuclease-free water). The thermal profile used was: 95 °C for 20 s, followed by 40 cycles of 95 °C for 
3 s and 60 °C for 30 s. The experiment was completed using a RotorGene 6000 qPCR instrument (Qiagen, 
Hilden, Germany). Data were normalised to the appropriate reference gene and analysed for expression 
level changes (ratio compared to untreated) using the ΔCq method with efficiency correction. The 
efficiencies for all PCRs ranged between 1.91 and 2.03, where 2.0 represents 100% efficiency. 
2.6. Statistical Analyses 
All data were analysed for statistical significance using a one-way ANOVA with SigmaStat 12.3 
(Systat Software Inc., San Jose, CA, USA). The normality of the data was tested using the Shapiro-Wilk 
method and the equality of variance using the Leven Median test. Non-normally distributed data was 
ranked and analysed using the Kruskal-Wallis ANOVA method. Following ANOVA, significantly 
different means were identified using the Dunnett’s post-hoc test. A probability (p) value of less than 
0.05 was considered to show a significant difference. 
3. Results 
3.1. ENL Reduces the Viability of Mid to Later Stage Prostate Disease Cell Lines 
ENL exerted differential effects on the mitochondrial metabolic activity and growth kinetics of the 
prostate cell lines at 24 and 48 h of exposure (Figures 1 and 2). 
At 24 h, 20 μM ENL or greater significantly reduced the metabolic activity of the WPE1-NB14, 
WPE1-NB11, WPE1-NB26, and LNCaP cell lines. At 48 h, 40 μM ENL or greater reduced the activity 
of all cell lines. However, the activity of the WPE1-NA22 (10 and 20 μM), WPE1-NB14 (10 and 20 μM), 
WPE1-NB11 (10 and 20 μM), WPE1-NB26 (10 and 20 μM), and LNCaP (20 μM) cell lines was reduced 
at this time point. The RWPE-1 cell line tolerated up 40 μM ENL without significant alterations in 
metabolic activity. The metabolic activity of the WPE1-NB44, WPE1-NB11, WPE1-NB26, and LNCaP 
cell lines were significantly reduced in a dose dependent manner at concentrations of 20 μM of greater 
at both time points. The WPE1-NB14 and WPE1-NB11 cells were particularly sensitive to ENL at 24 
and 48 h. 
These data indicate that the lowest concentration of ENL that affects the metabolic activity in the 
“diseased” cell lines, but does not affect the “normal” cell line is 20 μM. As 40 to 100 μM ENL clearly 
affected all cell lines, these concentrations were excluded from further analysis. As changes in metabolic 
activity may result in altered growth rates, i.e., a change in the time taken for a population of cells to 
double in number, we measured the doubling times of the cell lines in response to 10 and 20 μM ENL 
over 48 h. 
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Figure 1. The effect of ENL on the metabolic activity of prostate cell lines over 48 h. The 
data are expressed as the mean absorbance ±SEM (n = 24). A statistical difference between 
untreated and treated samples is indicated by * (p < 0.05), ** (p < 0.01), or *** (p < 0.002). 
 
The growth kinetics, based on the time for the population to double in number, of the RWPE-1 and 
WPE1-NA22 cell lines were unaltered by ENL. The positive control, 20 μM etoposide, significantly  
(p < 0.018) decreased the metabolic activity and increased in the doubling time of the cell lines over 
48 h. The WPE1-NB14, WPE1-NB11, and WPE1-NB26 cell lines were the most sensitive to the  
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ENL-induced increased doubling time (i.e., slower growth) of these cell lines. The doubling time of the 
LNCaP cell line was only affected by 20 μM ENL. 
As 20 μM ENL was the lowest concentration that affected both the metabolic activity and doubling 
times of the WPE1 and LNCaP cell lines, but not the RWPE-1 cell line (the least diseased cell line in 
our model and an approximation of a “normal” cell line) this concentration was selected for further study. 
Figure 2. The effect of ENL on the doubling times of prostate cell lines over 48 h. The data 
are expressed as the mean doubling time ±SEM (n = 3). A statistical difference between 
untreated (UNT) and treated samples is indicated by * (p < 0.05), or ** (p < 0.01). 
 
3.2. ENL Restricts the Cell Cycle of and Induces Apoptosis in Mid to Later Stage Prostate Disease 
Cell Lines 
The restriction of cell cycle progression in the cell lines with 20 μM ENL over 48 h is shown in 
Figures 3 to 4. The positive control, 20 μM etoposide, significantly increased the S-phase and level of 
apoptosis of the cell lines over 48 h (p < 0.014). 
At 24 h, there was an increase in the percentage of cells in the G0/G1 phase of the cell cycle for the 
RWPE-1, WPE1-NB14, WPE1-NB11, WPE1-NB26, and LNCaP cell lines in response to 20 μM ENL. 
For the LNCaP cell line there was also decrease in the percentage of cells in the G2/M phase. At 48 h, 
the cell cycle of the WPE1-NB14 and WPE1-NB11 cell lines remained altered (NB14: increased G0/G1, 
decreased S, and NB11: decreased G0/G1, increased S, decreased G2/M) by ENL. The G0/G1 and G2/M 
phases of the LNCaP cell line were also restricted, both reduced, after 48 h. 
The data in Figures 3 and 4 also show that 20 μM ENL induces apoptosis in the WPE1-NB14,  
WPE1-NB11, and WPE1-NB26 after 24 and 48 h. At 48 h, the WPE1-NA22 and LNCaP cell lines also 
had increased levels of apoptosis in response to ENL. 
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These data indicate that the disrupted viability (metabolic activity and doubling times), shown in 
Figures 1 and 2, of the cell lines is due, in part, to alterations in cell cycling and cell death. Given the 
alterations shown Figures 3 and 4, the effect of 20 μM ENL on the expression of genes involved in two 
key pathways during abnormal growth and carcinogenesis was quantified to explore potential 
mechanisms of action. 
3.3. ENL Alters the Expression of DNA Licencing Genes in Mid to Later Stage Prostate Disease Cell Lines 
The expression of the DNA licencing genes in response to 20 μM ENL by the six cell lines are shown 
in Figure 5. The co-efficient of variation for the HPRT1 reference gene amongst the untreated cell lines 
was 9% and 5%, at 24 and 48 h respectively. These data show that the expression of GMNN (CDT1 
inhibitor) is increased approximately 2 to 3 fold in the WPE1-NB14 and WPE1-NB11 cell lines after 24 
and 48 h. The expression of CDT1 was reduced in these cell lines by approximately 2 fold. The 
expression of the MCM2 and 7 genes was reduced in the majority of cell lines at 24 h, but only in the 
WPE1-NA2, WPE1-NB14, and WPE1-NB11 cell lines at 48 h. These changes in expression imply that 
the licencing of DNA for replication is reduced and would results in cell cycle restrictions (particularly 
in the G0/G1 and S phases), reduced proliferation, and/or increased cell death. 
The reduced expression of MCM7 suggests that the miR-106b cluster (located in one of the introns 
of MCM7) may also be influenced by ENL and if so this may affect the expression of the PTEN gene. 
3.4. ENL Alters the Expression of the miR-106b Cluster Leading to Increased PTEN Expression 
The expression of the miR-106b cluster and PTEN genes in response to 20 μM ENL by the six cell 
lines are shown in Figure 6. The co-efficient of variation for the rnu6b reference gene in the untreated 
cell lines was 2.3% and 2%, at 24 and 48 h respectively. These data show that the expression of  
miR-106b, miR-93, and miR-25 are decreased in the WPE1-NB14, WPE1-NB11, WPE1-NB26, and 
LNCaP cell lines after 24 and 48 h. The expression of PTEN is substantially increased in the WPE1 and 
LNCaP cell lines. 
These data suggest that the repression of the miR-106b cluster leads, in part, to increased PTEN 
expression. However, the expression of PTEN was increased by ENL in the WPE1-NA22 cell line 
despite no substantial change in the expression of the miR-106b cluster. 
  
 
Nutrients 2014, 6 4847 
 
Figure 3. The effect of 20 μM ENL on the cell cycle profile of prostate cell lines after 24 h. 
The data are expressed as the mean percentage of events in each phase ±SEM (n = 3). A 
statistical difference between untreated and treated samples is indicated by * (p < 0.05),  
** (p < 0.01), or *** (p < 0.002). 
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Figure 4. The effect of 20 μM ENL on the cell cycle profile of prostate cell lines after 48 h. 
The data are expressed as the mean percentage of events in each phase ±SEM (n = 3). A 
statistical difference between untreated and treated samples is indicated by * (p < 0.05), ** 
(p < 0.01), or *** (p < 0.002). 
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Figure 5. The effect of 20 μM ENL on the expression of DNA licencing genes by prostate 
cell lines over 48 h. The data are expressed as the mean expression level ±SEM (n = 3). For 
each cell line, a difference between untreated and treated samples is indicated by * (p < 0.05), 
** (p < 0.01), or *** (p < 0.002). 
 
  
 
Nutrients 2014, 6 4850 
 
Figure 6. The effect of ENL on the expression of the PTEN gene and miR-106b cluster 
genes by prostate cell lines over 48 h. The data are expressed as the mean expression level 
±SEM (n = 3). For each cell line, a difference between untreated and treated samples is 
indicated by * (p < 0.05), or *** (p < 0.002). 
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4. Discussion 
The present study provides further evidence that a pure mammalian lignan inhibits the in vitro 
proliferation of prostate cell lines. To our knowledge, this is the first study to examine the correlation 
between the expression of genes associated with DNA licencing and miR-106b cluster mediated PTEN 
and biological end-points of proliferation in vitro. 
Previous in vitro studies examining how the prostate cell lines respond to ENL have reported  
anti-proliferative effects for concentrations ranging from 25 to 100 μM and our data are in agreement 
with these findings [18,20]. In contrast to the previous studies we have studied the effects of ENL on the 
proliferation of a range of prostate cell models, rather than the late-stage models generally used, and 
explored potential mechanisms of action. We have shown that ENL at 20 μM over 48 h is sufficient to 
restrict the proliferation of primarily mid to later stage prostate cancer cells without any effects on the 
approximately “normal” RWPE-1 cell line. However, this cell line is immortalised and is not truly 
normal. Additionally we have shown that the anti-proliferative effects of ENL are strongly associated 
with: (1) improved negative regulation of abnormal DNA licencing (increased GMNN expression and 
decreased CDT1 expression); and (2) inhibition of miR-106b cluster expression leading to increased 
expression of the tumour suppressive gene PTEN. 
The ENL-induced changes in genes required for DNA replication initiation may explain the effects 
of ENL on cell cycle control and consequently proliferation in the prostate cell lines. However, the effect 
of altering the GMNN/CDT1 balance in tumourigenic cells (which express higher levels of these genes 
compared to normal cells [31]) is unclear as there is debate about how the GMNN/CDT1 balance 
influences the development and progression of cancer [26–28,39,40]. Additionally we have also shown 
that the expression of MCM2 and MCM7 is reduced by ENL in the prostate cell lines used, and this may 
be linked altered CDT1 expression as CDT1 is required for the loading of the MCM complex during the 
initiation of DNA replication [24]. MCM7, in particular, is known to be oncogenic [25,29,41] not only 
for its role in DNA licencing, but also due to other interactions such as: (1) MCM7 overexpression can 
inhibit the retinoblastoma-controlled cell G1/S cell cycle block [42,43]; (2) MCM7 interacts with the 
androgen receptor [44], appropriate androgen signalling and the consequences of androgen insensitivity 
are key factors in prostate carcinogenesis and relapse [45,46]; and (3) one of the introns of MCM7 
contains the mir-106b cluster [35] which targets two key tumour suppressor genes implicated in the 
prostate cancer, PTEN and CDKN1A (p21) [47–49]. 
Reduced PTEN expression can contribute to cancer development due to decreased negative regulation 
of the PI3K/AKT pathway (known as quasi-sufficiency) [50]. Unlike the classic “two-hit” model of 
tumour suppression, it is the amount of functional PTEN (which can be affected by several factors not 
just transcription) that determines its tumour suppressive capacity. We have shown that ENL can 
increase PTEN expression, which may restore the appropriate regulation by PTEN of the PI3K/AKT 
pathway. However, the LNCaP cell line has a mutated and non-functional PTEN gene [32] and therefore 
the consequence of its increased expression by ENL is unclear. 
The concentrations used in this study have yet to be shown to be achievable in the prostate in vivo 
either through dietary or pharmacological intervention. We also have only demonstrated a link between 
gene expression and proliferation markers—further work is needed to establish whether the expression 
changes result in functional changes at the post-transcriptional level. We have shown that there appears 
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to be a relationship between ENL-mediated expression of the PTEN gene, perhaps via suppression of 
the miR-106b cluster, and proliferation in prostate cancer cell lines. If these are confirmed at the proteomic 
and functional level, it may represent a novel mechanism for the anti-proliferative activity of ENL. 
5. Conclusions 
In conclusion we have provided evidence for the anti-proliferative effects of ENL in mid and late 
prostate cell lines, and have shown that changes in the transcription of DNA licencing, miR-106b cluster, 
and PTEN genes may be involved in these effects. This is important as we have shown that ENL is 
effective in earlier stages of prostate cancer than previously reported and two important pathways in 
prostate tumourigenesis are linked through miRNA effects. 
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